Investors Investors

Stock Quote

Stock Quote

11:08 AM EDT on Sep 20

Press Releases

Press Releases

All Releases
Sep 17, 2018

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA ® (iobenguane I 131), the Company’s radiotherapeutic, has

Sep 12, 2018

-Meets Co-Primary Endpoint of Specificity; 1404 Successfully Identifies Patients Without Clinically Significant Prostate Cancer- -Co-Primary Endpoint of Sensitivity to Identify Patients with Clinically Significant Disease Not Met- NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Progenics

Aug 08, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common stock at a public offering price of $8.25 per share. The gross proceeds from the sale of the primary

Aug 07, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement.

Jul 31, 2018

AZEDRA ® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA); U.S. Promotion Commences Top-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404 Expected in Q3’18 Top-Line Data from Phase 2/3 Trial for PSMA-Targeted PET/CT Imaging Agent PyL ™ Expected in

Jul 30, 2018
The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and Older Company to Host Conference Call Tomorrow at 8:00 AM ET NEW YORK , July 30, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that the U.S.
Jun 26, 2018
Top-line Data Expected in 4Q2018 NEW YORK , June 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, today announced that it has completed enrollment in its Phase
Jun 25, 2018
Algorithm Validated Using Data from Company's 1404 Phase 2 Study NEW YORK , June 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, reported data demonstrating the
Jun 04, 2018
NEW YORK , June 04, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced updated overall survival data from the Company’s pivotal Phase 2 trial of its targeted,
May 31, 2018
NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the Jefferies 2018
May 31, 2018
NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that an abstract describing the Company’s imaging analysis technology will be
May 22, 2018
Data Support Prognostic Utility of aBSI as an Imaging Biomarker for Survival in Patients with Castration-Resistant Prostate Cancer NEW YORK , May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated
May 09, 2018
Pre-Commercial Launch Preparations Underway for AZEDRA ® (iobenguane I 131) ahead of U.S. Food and Drug Administration ( FDA ) July 30 th Action Date Top-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404 Expected in Q3’18 Enrollment Expected to Complete in Phase 2/3 Trial
May 02, 2018
RELISTOR® Injection Protected from Generic Competition Until 2024 NEW YORK , May 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) reported that its partner Valeant Pharmaceuticals International, Inc. today announced that the U.S.
Apr 26, 2018
NEW YORK , April 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference call and webcast to review the first
Apr 25, 2018
Pivotal Phase 2 AZEDRA Data Selected for Oral Presentation NEW YORK , April 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that two
Apr 02, 2018
NEW YORK , April 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the H.C.
Mar 22, 2018
NEW YORK , March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that the Company has received notification from the U.S.
Mar 20, 2018
NEW YORK , March 20, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the 17th
Mar 19, 2018
Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA NEW YORK , March 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and